Cytokinetics, Incorporated (CYTK) Earnings Call Transcript & Summary

May 6, 2021

NASDAQ US Health Care Biotechnology earnings 78 min

Earnings Call Speaker Segments

Diane Weiser

executive
#1

Thanks for joining us this afternoon. Our President and Chief Executive Officer, Robert Blum, will kick off the discussion with a look at the quarter and some recent news. Then Fady Malik, who is our EVP of Research and Development, will give an update on omecamtiv mecarbil — including where things stand following a recent FDA meeting, what upcoming analyses from GALACTIC-HF should show, that being the positive Phase 3 clinical trial of omecamtiv mecarbil, and recent work related to METEORIC-HF, the second Phase 3 clinical trial of omecamtiv mecarbil. After that, Stuart Kupfer—our SVP and Chief Medical Officer—will provide an update on the cardiac myosin inhibitor program, focusing on REDWOOD-HCM, the Phase 2 clinical trial of CK-274. Next, Robert Wong, VP and Chief Accounting Officer, will review the financials from the last quarter; then Ching Jaw, our SVP and Chief Financial Officer, will discuss financial outlook and corporate development strategies, after which Robert Blum will return to share closing remarks and key milestones anticipated for the rest of 2021. Joining us on today's call is someone new: Andrew Callos, our Chief Commercial Officer, who came aboard Cytokinetics during the quarter and whom you'll be hearing from on future calls. Before we continue, note that some of what we say next — including answers we give to your questions — will address upcoming events and results instead of things that have already happened, which makes those remarks forward-looking. What we ultimately report could end up substantially different from what those forward-looking remarks anticipate. You can find more details about the factors that might make our actual results diverge substantially from what those remarks anticipate in the documents we file with the SEC, among them our current reports covering our first quarter 2021 financial results, which we filed today on Form 8-K. Once this call ends, we are not committing to revise any forward-looking remarks. With that, I'll hand things over to Robert.

Robert Blum

executive
#2

Thanks, Diane, and I want to express my appreciation once more to all of you for being with us on today's call. Our first quarter was productive, and we're growing more encouraged as the country moves back toward new forms of normal over the next few months, driven by broad COVID-19 vaccination. Our best wishes remain with each of you and your families for good health and wellbeing; beyond that, we're upbeat regarding Cytokinetics — our pipeline, the progress we're making, and what lies ahead. During the first quarter, we performed strongly against our objectives and everything is clicking. Our top priority is pushing forward the cardiovascular drug candidates aimed at muscle that lead our industry, with attention centered on both REDWOOD-HCM and METEORIC-HF, along with moving ahead on regulatory and commercial readiness efforts supporting omecamtiv mecarbil. With that in mind, it's a real pleasure to welcome the newest addition to our leadership team, Andrew Callos. Andrew has come aboard as our Chief Commercial Officer, and having him with us is exciting at such a pivotal moment for the company, as we round the bend toward commercialization and shift into becoming a forward integrated biopharmaceutical company. Andrew carries relevant commercial and operational know-how from cardiovascular specialty care and rare disease markets. His career at Pfizer and at Wyeth Pharmaceuticals was long tenured and successful, and there he supervised U.S. and international pharmaceutical business franchises. In his most recent position, Andrew was Regional President and General Manager North America for Pfizer's Upjohn Business Unit. Before holding that role, and across his more than 20 years at Pfizer and predecessor companies, his leadership posts included Vice President U.S. Cardiology & Metabolic Marketing, where he was in charge of commercializing Eliquis in the United States. Andrew also held the positions of Vice President and Head of Inflammation Marketing Europe and Vice President Global Commercial Development for Rare Diseases. As is evident, his background suits Cytokinetics perfectly, and he has gotten up to speed quickly and pitched in on the numerous commercial planning work streams that were already in motion before he arrived. Andrew is here to head a group of equally expert commercial colleagues at Cytokinetics who bring experience in cardiovascular and neuromuscular specialty care markets. And as we finish our go-to-market planning for omecamtiv mecarbil and CK-274, you'll be hearing additional details from Andrew and his team about our plans, including at an Investor Day set to be scheduled later this year. Regarding the regulatory side, as we said before, we convened an FDA meeting in the first quarter to review the Phase 3 clinical trial results from GALACTIC-HF. And we are now moving toward further interactions with FDA and other regulatory authorities. Fady is going to go into detail shortly, but let me just say that the engagement level and the feedback from FDA left us encouraged, and we feel GALACTIC-HF is capable of standing alone as a pivotal trial within a planned NDA submission. Our sights are now set on reaching our objective of submitting an NDA for omecamtiv mecarbil during the second half of 2021. Beyond that, we moved our go-to-market planning forward through work streams centered on market research, brand positioning, supply chain manufacturing and logistics, market access, health economics and outcomes research, customer engagement, and other commercial infrastructure — all of it meant to shape our future investment and execution strategies and to get us ready for a possible commercial launch of omecamtiv mecarbil in the United States in 2022. Ching is going to go into more detail later on this call about our financials, our cash runway, and our deal objectives in support of that go-to-market strategy. During the quarter we likewise achieved meaningful progress on our cardiac myosin inhibitor program, with attention centered on finishing REDWOOD-HCM, the Phase 2 clinical trial of CK-274 we currently have underway in patients who have symptomatic obstructive hypertrophic cardiomyopathy. As Stuart is going to detail in the first quarter, we opened Cohort 2 and got enrollment finished quickly, and more recently we opened enrollment for Cohort 3. On top of that, this morning we shared that the first site has also been activated in the open-label extension study for patients who finished REDWOOD-HCM. Execution at this level of proficiency highlights how urgent our work in this program is, given how much unmet need exists among patients with hypertrophic cardiomyopathy. Drawing on the interim analysis data for Cohort 1 that we released in December, our plan is to engage FDA this quarter and get ready for a Phase 3 clinical trial that should start before year end. We are additionally pushing ahead with medical and new product planning activities aimed at specialty care cardiologists at high volume heart failure hospitals that overlap with high volume HCM centers of excellence, since there are so many synergies between our cardiac myosin modulators and planning. With that, I will now hand the call over to Fady to go into detail on developments tied to omecamtiv mecarbil.

Fady Malik

executive
#3

Thank you, Robert. In Q1, we moved omecamtiv mecarbil ahead on a number of fronts that matter. To start, we sat down with the FDA to go over the top-line findings from GALACTIC-HF; that Type C meeting came in where we hoped it would, both in terms of the dialogue and the input we received, and we now plan to move toward submitting an NDA later this year, drawing on the GALACTIC-HF results along with the balance of the development program. We got the chance to hear from the FDA about the issues we ought to be ready to tackle as we wrap up the NDA filing. Right now we're getting set for further talks with the agency in Q2, among them another plan Type C meeting that we anticipate will sharpen our filing strategy even more. When that next meeting happens, we intend to present extra analyses from GALACTIC-HF and seek the FDA's input to shape labeling and our NDA submission. We anticipate even more interactions beyond that, possibly a pre-NDA meeting, and we're glad to have so many chances to work with the FDA before our aim of filing an NDA in the year's second half. Let me remind you that the NDA we intend to submit will rest on GALACTIC-HF's findings together with the remainder of the development program, which spans more than 30 clinical trials, and will reflect what prior regulatory conversations have taught us; alongside all of this, we're still running METEORIC-HF, our second Phase 3 trial of omecamtiv mecarbil in patients who have heart failure with reduced ejection fraction; and in METEORIC-HF, we're looking into whether omecamtiv mecarbil might improve exercise tolerance among heart failure patients, which could deliver a benefit to those patients who struggle with everyday activities. Screening has almost wrapped up, and we remain on schedule to finish randomizing patients into METEORIC during this second quarter. We anticipate top-line data becoming available in early 2022. Should METEORIC read out positively, we'd expect those trial data to go in as a supplemental filing, which would be expected to come after a possible FDA approval and commercial launch. I want to recognize the study team, the investigators, and the study coordinators for their dedication in reaching this milestone successfully amid a pandemic unlike anything we've seen. This quarter, we learned that data from a secondary analysis of GALACTIC-HF evaluating how omecamtiv mecarbil affects clinical outcomes in relation to baseline ejection fraction will be presented by Dr. John Teerlink during a late-breaking clinical trial session at the American College of Cardiology 70th Annual Scientific Session; we're not able to say anything further about those data. That's to respect embargo rules, but it's fair to say we think it will deepen understanding of which GALACTIC-HF patients gained the most from omecamtiv mecarbil added on top of standard of care. The GALACTIC-HF executive committee, working alongside Cytokinetics, has been engaged in a number of further secondary analyses. Data from these will arrive later in the year, both at medical meetings and through manuscripts, so that the GALACTIC-HF findings can be elaborated on more fully and its possible use clarified. Our view is that these extra analyses will shed considerable light on how omecamtiv mecarbil performed in GALACTIC and will surface important learning. Because the heart failure treatment landscape keeps shifting, we have an obligation to grasp as well as possible how these data should be framed, and what might become an approvable submission for this first-in-class cardiac myosin activator, which lowered the risk of heart failure events in its pivotal trial. Along those lines, during the last quarter we carried on with market research work aimed at better defining and refining the potential target product profile for omecamtiv mecarbil, and at understanding where it might most appropriately fit within the treatment armamentarium, especially in light of the new entries clinicians and their patients now have available. As we have noted previously, this is an exciting period in heart failure treatment, where unmet need remains tremendous, and we stay enthusiastic that omecamtiv mecarbil could offer a welcome addition in the struggle to better manage this progressive disease of high prevalence — particularly for more severe patients who have exhausted guidelines directed therapy yet continue to suffer debilitating symptoms or face elevated risk of heart failure hospitalization. We also were able to engage with a great many KOLs over the quarter, and a significant majority of them expressed positive views about omecamtiv mecarbil. Importantly, they pointed out that it could potentially fill a key need among a more severely ill patient population at greater risk of hospitalization and re-hospitalization. Among the common themes was an understanding that, biologically, it stands to reason that patients whose cardiac systolic function is more impaired may benefit more from this novel mechanism therapy, which is designed to act directly on muscle and thereby improve cardiac function and performance. Another theme was the potential to add omecamtiv mecarbil to standard of care, given its favorable tolerability and safety profile as observed in GALACTIC-HF, and the fact that adding it to standard of care did not adversely affect blood pressure or renal function. Finally, during the past quarter, we were pleased to hold an inaugural meeting of our heart failure patient advisory council. This group consists of passionate patients and caregivers, with whom we have been meeting regularly to inform understanding of the patient experience, the disease journey, and unmet needs; these insights will be instrumental in designing patient support services, educational materials, and guiding the development of our heart failure directed pipeline. We are grateful to the participants. From our first engagement, we are confident this group will be valuable to our patient-centric activities. As we have indicated, Cytokinetics is committed to advancing omecamtiv mecarbil as a key priority in 2021. Accomplishing that demanded considerable focus on winding down operations, and one of those efforts involves our work with Amgen, which covers handling the handoff of the integrated safety database along with associated reporting duties, obtaining regulatory paperwork, and taking on manufacturing responsibility. Moving all these work streams away from a partnership that has lasted 15 years is no small matter. Our Cytokinetics team has been working very diligently on these matters to make sure the handoffs go smoothly and in an orderly way. As you would expect, omecamtiv mecarbil has been our top priority, so we are reducing the priority given to advancing further development of CK-136, our cardiac troponin activator, which was previously called AMG 594, and that work will be put off through the remainder of 2021. We intend to resume its development down the road as we keep building our pipeline ahead of time and seek to grow our newly emerging cardiovascular product franchise. With that, I will hand the call over to Stuart.

Stuart Kupfer

executive
#4

Thank you, Fady. Over the past quarter, our cardiac myosin inhibitor program achieved meaningful strides, with attention centered on moving CK-274 forward. First, I'll share news regarding REDWOOD-HCM, the Phase 2 study of CK-274 in individuals who have obstructive HCM, which covers a recap of recent regulatory discussions along with those coming up, and after that I'll mention preclinical findings presented not long ago at the American Chemical Society Annual Meeting. In REDWOOD-HCM's first quarter, the initial participant received a dose, and we also finished enrolling everyone in Cohort 2, which is looking at how safe and well tolerated 10, 20 and 30 milligram doses of CK-274 are compared with placebo. For each patient, CK-274 dosing gets titrated individually using echocardiography at weeks two, four and six, with the dose fine-tuned according to desired decreases in LVOT gradients while keeping ejection fraction normal. In total, treatment lasts 10 weeks, with an echocardiogram performed to check whether the effect reverses two weeks following the final dose. We are still on schedule to share top line findings from Cohort 1 as well as Cohort 2 at mid-year, and to start planning a Phase 3 clinical trial before the year ends. Earlier this week, we disclosed that Cohort 3 of REDWOOD-HCM is now open. The purpose of Cohort 3 is to look at how safe and well tolerated CK-274 is among patients whose background therapy involves disopyramide, a drug sometimes given to those whose symptoms don't respond to first-line medical treatment, and one that most HCM intervention trials today have excluded. Those in Cohort 3 will get CK-274 in an open-label manner across a 10-week span, with dose titration individualized at 5, 10 or 15 milligrams taken once daily. This cohort isn't meant to further hone the dosing approach we plan to use in Phase 3; rather, Cohort 3 should yield valuable data that helps shape whether disopyramide treated patients can be included in the Phase 3 clinical trial we intend to run. Also, this morning, we shared that the first site has been activated in REDWOOD-HCM OLE, an open-label extension study whose aim is evaluating CK-274's long-term safety and tolerability among patients with symptomatic obstructive HCM. To be eligible, patients must have finished taking part in Redwood-HCM. Our main focus will be long-term safety, measured through how often adverse events occur and left ventricular ejection fraction below 50%. Secondary endpoints cover long-term impacts of CK-274 on left ventricular outflow tract gradient along with steady state pharmacokinetics assessments. A cardiac MRI sub-study will also be part of the open-label extension, evaluating shifts in cardiac morphology function and fibrosis. Every patient enrolled gets CK-274, with echocardiography guided dose titration to an individually optimized dose similar to what Redwood-HCM used. Last quarter, we also advanced our work with Ji Xing Pharmaceuticals, launching a Phase 1 clinical study of CK-274 among healthy participants in China. This is consistent with the goal we all share of getting China involved in a worldwide Phase 3 clinical trial that is set to start later this year. It is encouraging for us to observe that our colleagues at Ji Xing share our urgency in moving CK-274 forward into a global registration program. On the regulatory side, we were likewise glad to have recently obtained orphan drug designation from the FDA for CK-274 and symptomatic HCM, covering both obstructive and non-obstructive patients. That highlights a substantial unmet need and patients who go on experiencing separate symptoms that can seriously affect their quality of life. Only a handful of treatment options exist for them, and there are no approved medical therapies at present; during the first quarter, we also made preparations for regulatory interactions, among them Type C and end of Phase 2 meetings with the FDA, along with EMA for scientific advice. The earliest of these next level meetings is scheduled for the second quarter and will shape how we move toward an end of Phase 2 meeting that is anticipated in the third quarter. Lastly, last month, data concerning the optimization of CK-274, which included the first disclosure of its chemical structure, were presented at the American Chemical Society Spring 2021 Virtual Meeting. That scientific presentation brought attention to the preclinical characterization of CK-274 and centered on key compound characteristics, among them this half-life, the shallow dose response relationship and lack of meaningful cytochrome P450 interactions. In addition, data were presented from genetic models of HCM, in which CK-274 lowered fractional shortening and LVOT peak gradient in a dose related manner. Such results underscore the success of the chemical optimization program carried out at Cytokinetics, which was deliberately aimed at designing key compound characteristics to allow flexible, safe and timely dosing adjustments in clinical practice; we now anticipate results from both Cohorts 1 and 2 of Redwood-HCM, which will clarify how these next generation physicochemical properties of CK-274 might translate into important clinical effects in patients with obstructive HCM; and with that, I’ll hand things over to Robert Wong, who will give an update on our financials.

Robert Wong

executive
#5

Thanks, Stuart. First off, I want to bring you up to speed on where we stand with cash, revenue, and spending. Then Ching will take you through how we see the finances shaping up and what we're planning on the corporate development side going forward. If you want more granularity on what we actually posted for Q1 2021, you can find it in the press release that went out earlier this afternoon. When the first quarter wrapped up, we had about $460 million sitting in cash and investments. The revenue we booked in Q1 2021 was primarily attributable to the strategic alliances we have in place with Amgen and Astellas. On the R&D side, our expenses for the first quarter of 2021 climbed to $31.6 million, up from $21.7 million during the same period in 2020. The main reason for that increase was heavier outlays on our skeletal muscle program, along with clinical development work tied to our cardiac myosin inhibitor programs. Cardiovascular programs accounted for more than half of our R&D spending, which matched what we had anticipated because of work on METEORIC-HF and the cardiac myosin inhibitor program, while skeletal and early research efforts made up the remaining portion. G&A expenses for the first quarter of 2021 came to $15.6 million, compared with $12.4 million during Q1 2020, reflecting greater personnel-related costs, stock-based compensation among them, along with increased spending on commercial readiness. Ching will now walk through our planning and corporate development strategy.

Ching Jaw

executive
#6

Thank you, Robert. When the first quarter drew to a close, we held roughly $460 million in cash; turning to our 2021 financial guidance, our view is that forward cash runway extends beyond two years. We've also noted that financial guidance might be updated once commercial planning work tied to omecamtiv mecarbil and a possible 2022 product launch is finalized. Throughout the quarter, we examined commercial planning in depth and are putting together a thorough go-to-market strategy, which we'll bring before our board so we can secure alignment regarding the overall approach along with investment requirements. This plan consists of several components: evaluating the market, shaping the brand, securing market access, structuring the commercial organization, engaging customers both in person and digitally, managing the supply chain, handling information systems, and forecasting sales, expenses, and return on investment. As we advance these efforts to prepare for a potential launch of omecamtiv mecarbil, we are concentrating on the investments that deliver the greatest efficiency and yield. That approach lets us pave the way for commercializing omecamtiv mecarbil in 2022 and simultaneously puts Cytokinetics in the strongest position for possible growth of our cardiovascular pipeline and for commercializing CK-274. Whatever foundation we establish for omecamtiv mecarbil will be drawn upon to support the planned launch of CK-274, which will assume file. During this planning effort, we're also looking at how others in the industry operate so we can learn the best methods for improving how we grow franchises, particularly given the changes brought on by the pandemic. If we carry out our commercial strategies and plans, we might take on substantial extra costs that aren't reflected in the financial guidance we have right now; we anticipate that a portion or possibly all of those possible costs could be funded by bringing in more capital, whether through strategic partnerships that provide short-term cash infusions, or by purchasing equity and or debt financing, should we decide that makes sense. Finally, as we've mentioned before, we're moving forward with a corporate development strategy for 2021 that has two components. To start, we want to find a partner for development and commercialization of omecamtiv mecarbil and CK-274 in territories that complement the ones where we plan to launch the products ourselves. So in those other regions, we're right now in talks with possible partners in Japan and Europe. Next, we aim to explore royalty monetization opportunities and/or structured financing arrangements to help fund the commercial rollout of omecamtiv mecarbil and CK-274. During Q1, our conversations with prospective partners about moving this plan forward were positive and fruitful, and we're eager to continue those talks, which could lead to one or more deals in the back half of the year. Cytokinetics has consistently secured capital by drawing on a wide variety of transaction structures. We remain confident that bringing our product to market will be best supported by the way we keep turning our edge in muscle pharmacology into revenue. Having said that, I'll hand things back to Robert Blum.

Robert Blum

executive
#7

Appreciate that, Ching. Before I walk through what we expect on the milestone front for the rest of the year, let me pause and set the context for where Cytokinetics stands right now—particularly around the total clinical and economic toll that cardiovascular disease carries today. COVID has claimed well over 500,000 American lives, yet cardiovascular disease is still the number one cause of death among Americans, and it has taken even more lives during that same period. Plainly put, what cardiovascular disease does to patients, to caregivers, and to our healthcare system is still unacceptable. It's a privilege, honestly, to be in a position where we can make a genuine impact with treatments that work through new mechanisms—approaches that behave unlike anything on the market today and have the potential to benefit millions of patients dealing with different types of heart failure. What our Phase 3 studies have demonstrated is that adjusting cardiac myosin, either by activating it or by inhibiting it, can deliver clinically meaningful outcomes on registration endpoints that matter a great deal. Leading the way in biopharmaceutical science centered on cardiac muscle is something we're proud of, and there's real excitement on our side as we prepare for the commercialization phase—tackling it with the same rigor and skill we bring to mapping out an entirely new area of cardiovascular pharmacology. This has been a quarter where we got a lot done, as you've heard already, and everyone here feels motivated by the changes taking place across the company. We're continuing to execute on our plans for what may become our first approval from the FDA along with our first commercial launch, and we believe that sets us up to achieve what we call vision 2025. Among the goals of that vision is securing two to three approvals for our pipeline candidates over the coming years. Ching took everyone through the different pieces and work streams that make up our go-to-market approach in support of bringing omecamtiv mecarbil to market. Over the quarter, we kept up our market research with physicians and payers to sharpen our target product profile along with our grasp of patient journeys and treatment patterns for the severe heart failure patient, the person who stands to gain the most from omecamtiv mecarbil. We also got seriously underway in setting the design strategy for our commercial organization and the possible launch of omecamtiv mecarbil. Those efforts had started under our Amgen collaboration, and now they're being honed as that collaboration wraps up later this month. As we put together the framework and the plan for engaging customers around omecamtiv mecarbil, CK-274 stays very much on our radar, since our goal is to reap the rewards of a franchise-based model for the business—similar to how we chose a portfolio-based model in our work on muscle biology. I'd like to emphasize just how much the high volume centers that focus on heart failure and HCM coincide, both in terms of geography and institution. The money we're putting into sales and marketing infrastructure to back a possible launch of omecamtiv mecarbil will be paid down gradually and will set the stage for moving CK-274 forward and potentially commercializing it. Said differently, the benefits we've seen at Cytokinetics from scale and from working together in research and development across many years should serve us just as well when it comes to commercialization, because we expect to establish a cardiovascular medicine business built on revenue that can be maintained and expanded. Even though the things we're focused on first in 2021 are clearly our cardiovascular efforts, we also recognize that we need to continue getting ready for COURAGE-ALS, the Phase 3 study of reldesemtiv involving ALS patients. There's still a major gap in treatment options for ALS patients, and we intend to launch this study for possible enrollment once we have a clear picture of how we'll bring omecamtiv mecarbil to market and how CK-274 advances into Phase 3. During the quarter, we kicked off activities to get the clinical trial up and running, and that involved submitting materials to regulators and institutional review boards for COURAGE-ALS, getting ready for the study to potentially begin in the latter half of the year. To wrap up, with the second quarter of 2021 now behind us, we continue to feel excited about what lies ahead across the pipeline and about becoming a fully integrated bio-pharmaceutical company. In the back half of this year, Cytokinetics has a number of things to reveal. The most significant are the results coming soon from Redwood-HCM, along with possible progress on the regulatory front for omecamtiv mecarbil. We think this may be one of the strongest cardiovascular pipelines around. Our mission is to deliver potential medicines to patients whose cardiovascular disease involves impaired muscle function, with the goal of extending how well they live, and we're making moves to achieve that. Meanwhile, our research work continues to center on creativity and innovation, and those are also central to vision 2025. As a reminder, over the coming years our goal is to grow the development pipeline to 10 therapeutic programs — twice what it is now — and to take our discovery platform beyond the biomachinery of muscle contractility into muscle energetics growth and metabolism. Progress so far is solid, and within the next twelve months we anticipate choosing as many as two additional development compounds from our cardiac and skeletal programs so they can begin IND-enabling studies. We're eager to share more detail on these promising R&D programs during upcoming calls. With that, I'd like to review the milestones we expect for 2021. Regarding omecamtiv mecarbil, our plan is to sit down with the FDA during Q2 as part of ongoing talks tied to our objective of filing an NDA in the latter half of 2021. Enrollment of heart failure patients into METEORIC-HF should wrap up during this same second quarter of 2021. Additionally, we intend to sharpen both our go-to-market approach and the blueprint for a possible commercial launch across Q2 of 2021 and the rest of the year. As for CK-274, data from Cohorts 1 and 2 of REDWOOD-HCM are slated for release around the midpoint of 2021. During this second quarter, plus on into the back half of 2021, we intend to talk with regulators about our Phase 3 trial and development program, and by the close of 2021 we look to launch a possible Phase 3 clinical trial for CK-274. When it comes to reldesemtiv, we anticipate carrying on with start-up work for COURAGE-ALS, and enrollment could begin in the second half of 2021 — once more, this depends on our plans for moving omecamtiv mecarbil toward commercialization and CK-274 toward a potential Phase 3 clinical trial in obstructive HCM patients. Turning to our ongoing research, we anticipate pushing programs forward and running IND-enabling studies that could move one to two potential drug candidates into development during 2022. Operator, at this point we're ready to take questions, please. Hello, Emanuela.

Emanuela Branchetti

analyst
#8

Good afternoon, everyone, and thanks for taking my questions. Congrats on how things are going with our programs. You said there's been a discussion with the FDA about omecamtiv and that it's going as expected. Could you give us more detail about which elements came up with the FDA and what remains to be talked through prior to NDA submission?

Robert Blum

executive
#9

Sure. I doubt we can add much beyond what was already said on this call, but to sum it up, perhaps: that initial meeting had the specific purpose of figuring out whether GALACTIC-HF on its own, with no additional Phase 3 clinical trial, could serve as standalone support for an NDA filing. We posed questions, there was discussion, and our takeaway from that call is that we received the answer we sought — namely, that we can move forward this way, preparing to submit an NDA grounded in GALACTIC alone; however, that represents only the start of a set of FDA interactions we had planned; and at this point, I'll hand things to Fady to discuss some of what we anticipate covering in other FDA interactions, among them a Type C meeting that's coming up.

Fady Malik

executive
#10

Sure, I might just address that from a broad perspective. Before submitting an NDA, I believe there are numerous elements to try to get FDA feedback on. These include how to approach labeling, how to approach dosing, and other items we’ll review with them regarding the program. That way, we can assemble a submission that I think supports the line, and understand what their input might be relative to our goals. And lastly, there are quite a few technical issues that need to be resolved with them concerning data standards and other parts of the program when one sends in a filing. Submitting an NDA is an enormous endeavor, and there are lots of specifics that it sometimes helps to get aligned on before you send in the paperwork, so you don’t have to work through those things afterward.

Emanuela Branchetti

analyst
#11

Understood, thank you. That is quite useful; and moving on to REDWOOD-HCM, could you perhaps help us set expectations for the data that is coming? What in particular ought we to zero in on, above all when thinking about possible comparisons with the Phase 2 data for mavacamten?

Robert Blum

executive
#12

Certainly. So once more, I will begin and then hand things to Fady and Stuart. As you are aware, we have already shared interim findings from Cohort 1, which we did at the close of last year. We went in with fairly elevated hopes. And I believe, frankly, we feel that interim Cohort 1 results went beyond those hopes, in that most patients saw clinically meaningful responses at the low end of the planned dose response curve; and none of those patients experienced EFs dropping under 50%. So we view that as boding well for finishing this study, Cohort 1 as well as Cohort 2. And since enrollment in Cohort 2 is now done, we will move toward database lock and the readout of those results. But regarding how that stacks up against another compound, please remember that this is a different study we are conducting; a head to head comparison is not what we are doing. We are, though, examining what we consider real world practice patterns in this trial on top of background therapy versus placebo, where we think this can best inform Phase 3. And with that, I will hand things to Fady and Stuart.

Fady Malik

executive
#13

I believe Robert already went through the bulk of this. I’ll keep my comments short, then — Cohort 1’s results left us pretty encouraged. As we’ve mentioned, most of the patients in that group hit the threshold at which we would halt escalation of drug therapy, though not all of them did. That’s precisely why we started Cohort 2, testing a bit higher doses to determine whether we could be sure of covering the upper end of the dose range. So the findings from Cohort 1 and Cohort 2 are going to guide the starting dose and, clearly, the maximum dose too. We’ll share that data in July, though in my view the key information concerns how the drug affects the left ventricular outflow tract gradient — when it goes down and by how much — and all of that ought to be presented quite clearly to everyone when we release the data midway through the year.

Emanuela Branchetti

analyst
#14

Understood. Thanks. About how many people are being enrolled in REDWOOD-HCM, at the start of this quarter it was optional, if my memory serves me right. Can you say more about why CK-274 would be combined with disopyramide?

Robert Blum

executive
#15

I'll hand that question to Fady or Stuart, whichever one would like to respond.

Fady Malik

executive
#16

Stuart, why don’t you take that question?

Stuart Kupfer

executive
#17

Okay, so the thinking behind this is that we've seen how patients dealing with more advanced symptomatic obstructive HCM will sometimes get put on disopyramide, and that drug is able to bring down cardiac contractility somewhat. But when you have patients who, even while on some standard therapies — disopyramide included — are still dealing with symptoms tied to HCM, a medication such as CK-274 could be of benefit to them, since it's specifically built to inhibit reduced cardiac contractility. So there's genuinely a possible upside for patients who have kind of exhausted their choices, if you will, and are further along in the natural history of the disease when it comes to how severe their condition is; another medical intervention, like CK-274, might help them, and that is truly what we aim to investigate — that more severe patient population, by adding to the disopyramide treated patient.

Emanuela Branchetti

analyst
#18

Understood. Thanks for that. Also, it appears to be < > open-label — would you anticipate putting out data while the trial is still going on, stopping before every patient has received a dose?

Robert Blum

executive
#19

My apologies. Stuart, could you handle that one.

Stuart Kupfer

executive
#20

Okay. My apologies if I took the question to be about putting out data for Cohort 3. Was that what you were asking?

Emanuela Branchetti

analyst
#21

Yes. Yes. What’s the timeline for that?

Stuart Kupfer

executive
#22

Well, let me begin by saying that data from Cohorts 1 and 2 will basically shape how we plan for Phase 3. I want to be very clear on this — those are the cohorts centered on our dose-finding goals. Eventually, that feeds into how we design our Phase 3 trial. Our plan is to launch that study by the end of the year. So Cohort 3 — how Cohort 3 is conducted, or when Phase 3 begins, does not depend on Cohort 3 finishing. That said, we'll put out the results, basically once we reach the point where that cohort is complete. That will probably be later in the year. But once again — at this moment we don't have a specific meaning or timeline; and again, it isn't linked to kicking off our Phase 3 trial.

Robert Blum

executive
#23

Yeah, it's likely that this open-label extension is going to keep producing data for some time and will give updates on how it's going at regular intervals.

Emanuela Branchetti

analyst
#24

Got it. Thank you very much.

Robert Blum

executive
#25

Thank you.

Robert Blum

executive
#26

Hi, Charles.

Charles Duncan

analyst
#27

Hi, Robert, and hello to the team. Thanks for fielding our question, and congratulations on the progress you've made with omecamtiv — really strong output this quarter. I'd like to ask about that FDA meeting you had recently. I realize you likely can't share specifics. But my first question is whether the meeting minutes have arrived yet. And second, did the FDA seem more swayed by the efficacy that showed up, or by the way you identified this high-burden and comparatively underserved patient group — probably both. Still, where do you sense their genuine interest lay?

Robert Blum

executive
#28

That's a fair question. First, on the minutes — yes, they've come in. As for your second point, I can't claim to represent FDA. But as you're probably aware, when a program includes more than 30 clinical trials plus a Phase 3 pivotal study enrolling over 8,000 patients across 35 countries, that's a fairly strong body of data we've built around omecamtiv mecarbil across 15 years. I don't believe FDA is just now waking up to the unmet need in heart failure. You've watched them step up when it comes to approvals in that area. Granted, those aren't drugs acting directly on cardiac muscle. And while I can't speak for FDA, since the GALACTIC results came out we've held a great many listening sessions with opinion leaders. One theme comes through consistently in those discussions — here is a chance we've long sought involving a novel mechanism therapy that binds directly to cardiac muscle, boosts cardiac function, lifts cardiac performance, and does all of that safely, with no arrhythmia risk, no heart rate issues, and without compromising blood pressure or renal function. That, in our view, is what omecamtiv mecarbil offers, potentially complementing standard of care — and remember, what we observed in GALACTIC came on top of standard of care. We think that points to a real opportunity set for omecamtiv mecarbil. We talked this over with FDA, and the feedback left us pleased. I hope that addresses your question.

Charles Duncan

analyst
#29

Yeah, absolutely — that captures the overall situation. Still, it really seems as though they factored in both the distinct mechanism of action and what the target product profile could be.

Fady Malik

executive
#30

What matters here is that the FDA has participated in numerous public gatherings alongside academics, biopharma companies, and heart failure researchers, all working to move this area forward. A few years back, you saw guidance issued that restated where they stand regarding what makes a heart failure drug approvable, and you'll notice that plenty of the agency's senior people take part in those meetings. I believe this simply shows people understand how big the unmet need remains, even with treatments already on the market. Take the event rates from GALACTIC — they're above 30%, and in certain sub-populations they run even higher. So despite the therapies available to us, the need is still enormous.

Charles Duncan

analyst
#31

Yeah, that makes sense. I realize there are going to be plenty of questions about CK-274 coming from other analysts, so I'll let them handle that. What I did want to ask you about is COURAGE-ALS. You brought up being ready to launch that Phase 3 once you'd finalized the omecamtiv go-to-market approach and possibly moved CK-274 into Phase 3. And what I'm sort of curious about is, what are the trigger points for COURAGE-ALS, if you're able to tell us, that you're waiting on in order to get that study operational?

Robert Blum

executive
#32

Sure. That's a good question. So first off, as you might remember, we shared the COURAGE-ALS design late last year. We've mentioned other secondary analyses too, and those give us confidence about approaches we think could improve the response seen at four to two days or shorter — something that's already part of the Phase 3 COURAGE-ALS design. We also shared that Astellas will co-fund COURAGE-ALS, and in return they'll get a low single-digit royalty on sales in certain countries. Along with that, we announced that interim analyses are built into COURAGE-ALS, which lets us check whether the study is confirming the kind of activity we designed and powered it to detect, drawing on what we saw in Phase 2. Okay. So, we did take some steps to prepare for a potential launch of COURAGE-ALS. But we're a small organization, and it's important that we maintain our priorities and stay focused. So before fully committing to getting COURAGE-ALS up and running operationally, we wanted to be sure we had a clear understanding of what the way forward looked like for both omecamtiv mecarbil and CK-274. And so we set out a few objectives, or milestones. The first one was that we wanted to see the results from GALACTIC — and now we have them. We also wanted to determine whether those results could support an NDA submission, and we believe we've received that feedback and that they can, and we anticipate filing in the second half of the year. We're also trying to get a handle on the go-to-market plan — what sort of ROI it can produce, what the timelines look like, what we'd be spending, what activities are involved — and we want to feel confident we have a solid grasp of all that. That work is underway right now. On top of that, we were looking to understand CK-274 and where Phase 3 might fit into its future; part of that has now been addressed, since interim data from Cohort 1 has come in and we're in discussions with regulatory authorities. We're getting ready for a possible Phase 3 before the year is out, though what we've gotten so far out of REDWOOD isn't sufficient for us to commit to COURAGE-ALS. We're looking to get that data so we can be in the strongest spot to confirm there's a viable route ahead for CK-274 into Phase 3, and that it could advance, possibly side by side with reldesemtiv in COURAGE-ALS at Phase 3. Imagine a company at that point with a particular shape: omecamtiv possibly hitting the market by 2022, along with two programs, one from each of our verticals, both in Phase 3 at some point in 2022. A profile like that is something we find attractive. We think it benefits shareholders and benefits our science, and that's where we've been aiming. And should anything have been gained by us throughout more than 20 years at Cytokinetics, it's that an advantage always exists in having one program positioned next up — having a program up serves the goal of constructing a sustainable and durable company, and managing a portfolio lets us build a franchise spanning both cardiac and skeletal muscle. So with COURAGE-ALS we aren't there yet, a few cards still need to be turned over by us, but we're getting there; meanwhile, startup activities have been under way on our part and we've been getting mobilized. Hopefully that's helpful.

Charles Duncan

analyst
#33

That's useful, Robert. Thanks for the considered reply and plan, and we appreciate your taking what we asked.

Robert Blum

executive
#34

Of course.

Robert Blum

executive
#35

Greetings, Salim.

Salim Syed

analyst
#36

Excellent. Hi there, Robert. Hi, everyone. I appreciate all the detail, and congratulations on the advancement. I have just 2 questions if that's alright. Fady, was my understanding correct — did you state that REDWOOD data arrives in July?

Fady Malik

executive
#37

My wording, I believe, was mid-year, in July, mid-year.

Salim Syed

analyst
#38

Right. But I believe you brought up that month — I just want to confirm I heard you correctly.

Fady Malik

executive
#39

I may have brought up that month. Given that enrollment is finished, the anticipated length of the study is finished, and so on, my guess is that we'll have those data read out at some point during July.

Robert Blum

executive
#40

Right. With that in mind, the database isn't finalized yet. The study is still ongoing. I've looked at your notes, and you've run some calculations and projections regarding timing. What I can tell you is that we're aiming for mid-year, and that remains to be determined, depending on things that still need to happen.

Salim Syed

analyst
#41

All right, understood. Let me just get some clarity on that point. If enrollment for Cohort 2 wrapped up in February — I think the announcement came on the 25th, if I'm not mistaken — why couldn't the database be locked 2 weeks after the week 10 treatment duration? At that final echo, what would prevent locking it at that point for Cohort 2 and sharing the data sooner? Just wondering.

Fady Malik

executive
#42

Salim, following week 10 there's actually a 4-week stretch. That means a 2-week echo at week 12, followed by a 2-week follow-up at week 14. During that stretch, every echo needs central reading and adjudication, plus the data have to be cleaned and so on. So that timeline involves database lock, core lab work, and similar activities.

Salim Syed

analyst
#43

Okay, understood. Then, for my second point, you're beginning to talk about the Phase 3 for CK-274, and I'm curious about your approach, given that mavacamten is already on the market and, if I recall correctly, the PDUFA date falls in January of 2022. Are you considering a head-to-head study against mava, or what exactly is your thinking here, with another HCM acid possibly reaching the market in the early part of 2022?

Robert Blum

executive
#44

That's a fair question, though I don't believe it would be sensible for us to answer it from the angle of competitive positioning, especially when we recognize there might be a single pivotal trial, or there might be more than one. In the end, we'll be determining the best way to position and frame CK-274 within what will be a dynamic space. We do anticipate that BMS should secure approval for mavacamten in 2022, yet we also hold the view that the trial we expect to run — at minimum the Phase 3 trial we've been aiming toward — is one that ought to enroll, well, not just within the United States, but beyond the United States as well. Our intention is to turn this into a global registration program. So I believe it then has the potential to still enroll quickly even while mavacamten may win approval in 2022. As for the head-to-head or anything along those lines, I think it would be too early for us to address any of those matters.

Salim Syed

analyst
#45

Got it. Thanks so much, guys.

Robert Blum

executive
#46

Thank you.

Robert Blum

executive
#47

Hello, Ted.

Ted Tentoff

analyst
#48

Excellent. I appreciate it very much. Hello everyone. How's it going? Thank you for the comprehensive briefing. My question, I suppose, pertains to omecamtiv mecarbil. That report left me feeling positive. And perhaps this is somewhat premature to bring up, but given what came out of GALACTIC, how would you characterize the market potential? Many thanks.

Robert Blum

executive
#49

Certainly. That's a valid question. I'll take that one on, though I'd also like to invite Andrew, who is on the line with us today, to offer his thoughts at a broad level, since his viewpoint differs from what some of us here at Cytokinetics might say. We have spent 15 years working on omecamtiv mecarbil in clinical trials. And sure, we are admittedly quite deep in the details, but he is able to take a broader perspective too, and because of what he knows about cardiology specialty care markets, I believe it would be useful for all of you to hear from him, at least on this initial occasion. What I can share with you is that right now in the United States, more than 6 million patients have heart failure. By 2030, that figure is expected to rise to between 8 million and 9 million. When you think about the fact that about 50% of them suffer from heart failure with reduced ejection fraction, and then you examine the data breakdowns — what portion has ejection fractions under 40, under 35, under 30, under 25 — real world evidence can provide that. A substantial number of patients meet those criteria, and that's similar to the way we pre-specified in GALACTIC for patients above and below the median. In GALACTIC, the median ejection fraction was 28%. More than 4,000 patients in GALACTIC fell into that group, and they represent, so to speak, patients dealing with more severe heart failure along with other risk factors. When you put those risk factors together, they describe a group of patients whose needs aren't being met by existing treatments, even with the standard of care in place. Since we're dealing in cardiology, the numbers aren't in the thousands or tens of thousands — they reach hundreds of thousands, and could even exceed a million patients. That's why positioning matters so much, and why we have to understand where omecamtiv mecarbil fits within guideline directed therapy. I think I'll leave it there and let Andrew share some of his thoughts.

Andrew Callos

executive
#50

Appreciate that, Robert. To add a bit onto your point — even though my time with the team has been pretty short, a great deal of our attention has gone into the go-to-market strategy, and based on the profile that Fady and Robert laid out, plus an add-on therapy, we're reaching the conclusion that, with the unmet need and how well omecamtiv's profile fits, a large number of patients stand to gain from the emerging profile of omecamtiv, and that we could also do very well commercializing it. Right now we're designing and building what we believe is a commercial organization and infrastructure of the appropriate size, one that lets us concentrate on the care settings where most heart failure patients receive treatment — both community cardiology and hospitals. So activating those cardiologists in those two care settings around omecamtiv for that subset of patients is really what will be essential to our success. And we feel, again, with the organization sized appropriately and the right ROI, that we certainly can succeed in this market.

Ted Tentoff

analyst
#51

Awesome. Thank you, guys.

Robert Blum

executive
#52

Thank you, Ted.

Robert Blum

executive
#53

Hello, Jeff. Jeff, you might be on mute.

Jeff Hung

analyst
#54

Are you able to pick me up?

Robert Blum

executive
#55

Yes, we're able to pick you up at this point.

Jeff Hung

analyst
#56

All right. Well, hi everybody, and I appreciate you taking my question, and welcome aboard, Andrew; this one's actually directed at Andrew, assuming he's available on the call. I suppose prior to your arrival at Cytokinetics, which elements of omecamtiv mecarbil or GALACTIC struck you as the most compelling? And at this point, being part of the company, what kinds of enhancements do you picture when it comes to the commercial push?

Andrew Callos

executive
#57

Absolutely, I appreciate the warm welcome. The largest factor is genuinely the science, the emphasis this organization places on science and how it aligns with what patients still lack, with real attention on muscle biology, cardiac myosin inhibitor, cardio myosin activators that genuinely align science with unmet need, that's truly the bedrock of what I considered wonderful for patients and wonderful for an organization to thrive. Having been at the company now for a few months, I believe what we've genuinely come to understand is that you must ensure you secure access to drugs and get cardiologists to truly grasp the evidence generated by a clinical trial such as GALACTIC-HF and using this evidence truly to paint a picture of who the obvious patient is that stands to gain the most from that, and then pulling the organization and the infrastructure into place with proper ROI and the rightsizing and structure for a company or a size kind of bringing these things together, access, drug profile, given the evidence in science and kind of our go-to-market strategy. That combination collectively will certainly bring us success.

Jeff Hung

analyst
#58

Thanks.

Robert Blum

executive
#59

I realize this inquiry wasn't aimed at me, yet there will be a chance for us to hear not just from Andrew but from people on his team too, since an Investor Day is scheduled for later in this year. Our plan is to describe our go-to-market approach in considerable depth. Rather than attempting to become a business that battles across all areas, we'll focus instead on where mechanistic science, the evidence, and our capacity to deliver a high ROI might set Cytokinetics apart in a market characterized by substantial unmet need, clinically as well as economically. Also, keep in mind the economic dimension, since, as has already been observed with GALACTIC-HF, omecamtiv added to standard of care produced meaningful decreases in hospitalizations and re-hospitalizations, and those hospitals must absorb those expenses for patients readmitted within 30 and 60 days. There's a highly persuasive chance for a pharmacoeconomic case here that, in our view, is quite logical to institutions and cardiologists treating patients at those institutions. So expect further updates on this, while acknowledging that as we move toward what we hope will be a launch of omecamtiv mecarbil, we will have set out our reasoning so others can grasp it as well.

Jeff Hung

analyst
#60

Great. Thanks.

Robert Blum

executive
#61

Thank you.

Robert Blum

executive
#62

Hey there, Dane.

Dane Leone

analyst
#63

Hey, things are good? Nice work on everything you've been moving forward.

Robert Blum

executive
#64

Doing well, appreciate it. Thanks a lot.

Dane Leone

analyst
#65

I'll keep it to a single question, since we're running somewhat late in this call. The — might you break this down for us, given that many inquiries have come in regarding what you revealed today about REDWOOD, specifically Cohort 1 against Cohort 2, and then the launch of Cohort 3 using disopyramide. Is it — perhaps to put it plainly, does the aim behind the Cohort 3 combination trial involving disopyramide serve to fulfill what much of the clinical community is looking for? The key point being a possible shortfall in what the mavacamten dataset produced. Or could there be some possibility that combining disopyramide with the Cohort 1 dose yields greater efficacy, which would remove any need to push CK-274 to the higher levels administered in Cohort 2? Thank you.

Robert Blum

executive
#66

That's a fascinating perspective. I hadn't considered it from that angle at all. It's very much intended to guide the potential enrollment of additional patients into Phase 3, though perhaps Fady or Stuart could elaborate on that point.

Fady Malik

executive
#67

Yeah. I think it's hard for me to comment on how everyone in the investigative community views this, except to say that these are patients who haven't gotten the chance to be in trials; we're getting ready to run a pretty large trial in this space. And if there's no reason they need to be left out, then why leave them out; so I think the way Cohort 3 is set up is to give us data on how safe it is to combine those two drugs, so that we can do that in an informed way.

Dane Leone

analyst
#68

Great. Thank you, guys.

Robert Blum

executive
#69

Thank you.

Robert Blum

executive
#70

Hello Greg.

Analyst

analyst
#71

Hi everyone, Anna here filling in for Greg. We have a single brief item regarding CK-274 Cohort 3, and the selected doses, which seemed somewhat lower compared to the other doses that were studied. Could you share some insight into how the doses for Cohort 3 were decided, and maybe also tell us how large an effect size you expect from Cohort 3 relative to what was observed earlier in Cohort 1? Thank you.

Robert Blum

executive
#72

Stuart, please go ahead and handle that.

Stuart Kupfer

executive
#73

Okay, so — we've talked about how disopyramide can lower cardiac contractility, and because of that, our intention is basically to assess that group of patients with care, which is what you'd anticipate. And as we laid out in our December press release along with the interim results from Cohort 1, we concluded that the lower dose range was safe and tolerable; therefore it made sense to study the disopyramide treated patients at those doses that had already been qualified, so to speak, and were understood to be safe and well tolerated. But there's another thing, and this is just to drive the point home, which is that dosing of CK-274 is individualized for every patient, correct. So that's based on hitting target gradients while keeping the ejection fraction reasonably normal. And so it's quite possible that certain patients on disopyramide will be well controlled and reach their target gradients within the lower dose range. And there are still some patients who might need higher doses, but ultimately, and we'll find this out in our Phase 3 trial — what kind of — by and large, what sort of doses are going to be needed, with the full dose range in Phase 3 and these patients treated with disopyramide.

Analyst

analyst
#74

Okay, great. Thanks so much.

Robert Blum

executive
#75

Thank you.

Robert Blum

executive
#76

Hi, Akash.

Andrew Newton

analyst
#77

Hi everyone, Andrew here filling in for Akash. I’ve got a few questions if that’s alright; but first off, could you give us some sense of the amount of relative decrease in contractility that’s required to relieve the outflow gradient? This is something that I think we’re aiming at pretty low on a dosing curve, let’s say, < > or thereabouts. Could you address that? Then second, regarding typical LVEF reductions across the cohorts and across whatever dose you might advance, when we consider the averages from the mavacamten trials, if you’re able to dose at a comparatively higher point on the dosing curve, because of the shallower relationship. Is it reasonable to say that we might observe a somewhat larger average EF decline? And then last, well, I realize we don’t want — everyone is going to examine these Phase 2 results and attempt to compare them with mavacamten, because of how the trial was designed and the titration scheme. Is it fair to say that the EXPLORER trial is actually a better comparator than the Phase 2 pioneer? Thanks.

Robert Blum

executive
#78

Those are all good questions. I’ll hand it over to Fady, and Stuart can probably field these better than, like…

Fady Malik

executive
#79

Alright, since time's running short, let me move through these fast. On your first point, how far ejection fraction has to fall before the gradient effect is maximized is still somewhat unsettled. It varies from one patient to another, I'd say. Typically, these patients come in with ejection fractions around 70%, 75%. That leaves them a good amount of room—considerable space to work with—when trying to get the most impact on the gradient. To put it briefly, we were expecting reductions somewhere between 5 and 15, with the range shifting based on the individual and how severe their gradient is. As for your second question—now I recall the third one too—but the second one concerned, could you remind me again.

Andrew Newton

analyst
#80

Yeah. So if the shallower PK/PD relationship does happen, would it be reasonable to expect the typical EF decline might be somewhat larger? Does that hint we could move somewhat higher up the dosing curve?

Fady Malik

executive
#81

Correct. Yes, I'd call that a sharp observation. A mean reduction in ejection fraction of 3%, 4%, 5% is quite modest when you consider, once more, the starting point for these patients. So, as I mentioned during the first question, if you're able to reliably increase the dose somewhat, perhaps even bring the ejection fraction down somewhat further, you'd still remain comfortably within the normal range. Yet you might be able to get a bigger effect in patients whose gradient is more severe. We hope to have some read on that once we see the complete data set from REDWOOD-HF, HCM I mean; and then I believe for the last question, the answer is that I think the EXPLORER data, in certain respects, the echocardiographic findings from EXPLORER are likely a stronger comparator for REDWOOD-HCM, given that it was a placebo-controlled study with patients receiving background therapy, while in their Phase 2 trial they had taken patients off background therapy. That was an open-label study. I think there are definitely distinctions between the two trials that truly prevent a head-to-head comparison, with caution toward people who always attempt to make those comparisons without grasping the underlying variables. But essentially, I think EXPLORER would probably be more applicable to the Redwood experience.

Andrew Newton

analyst
#82

Okay. Thank you.

Robert Blum

executive
#83

Thank you.

Robert Blum

executive
#84

All right. It seems we've gone over a great deal of material during the presentation and the Q&A, so I'll keep my remarks short. My thanks go out to each of you for tuning in and taking part in this 2021 earnings call — clearly, plenty of positive developments are underway at Cytokinetics. As we head into what's left of the year, our focus is sharp and centered on execution: reaching the REDWOOD-HCM results at mid-year, having a solid plan in place for omecamtiv mecarbil, and getting set to create what we believe could be a transformational period for Cytokinetics as we move toward a commercial stage, potentially in 2022. Simultaneously, we're intensifying our efforts in research and development — expanding our research platform and doubling our clinical research pipeline — and we aim to be among the companies building a franchise business. Alongside that, we keep pushing scientific innovation, advancing a sustainable pipeline, and shaping a durable business. I'm eager to share updates on how we're progressing. And we're ready to address further remarks and inquiries as time goes on. With that, operator, let's wrap up this call.

Operator

operator
#85

Everyone, that brings us to the end of today's conference call; we appreciate your participation. You are now free to disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Cytokinetics, Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Cytokinetics, Incorporated earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cytokinetics, Incorporated or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.